Ovarian Cancer Risk Assessment

BioReference Health®, LLC now offers Ova1Plus® with unparalleled abilities to detect ovarian cancer risk in women diagnosed with a pelvic mass planned for surgery1.

What is Ova1Plus®?

Ova1Plus is a reflex process which performs Ova1® and Overa®, both FDA-cleared tests for women with adnexal masses planned for surgery.

What are the benefits of Ova1Plus®?

The combination of Ova1 and Overa can hep you further stratify your patient’s risk of malignancy.

Ova1Plus®  Biomarkers (Ova1®)

For information on how to order the test, click here to visit our test directory or speak with your sales representative. Search for Tests | BioReference®

Ova1Plus® is an offering of Aspira Women’s Health.


1. Reilly, G. P., Dunton, C. J., Bullock, R. G., Ure, D. R., Fritsche, H., Ghosh, S., … & Phan, R. T. (2023). Validation of a deep neural network-based algorithm supporting clinical management of adnexal mass. Frontiers in Medicine, 10, 1102437.

2. Citation also:
Bristow, R. E., Smith, A., Zhang, Z., Chan, D. W., Crutcher, G., Fung, E. T., & Munroe, D. G. (2013). Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecologic oncology, 128(2), 252-259.

3. ACOG Practice Bulletin Number 174, November 2016​

4. SGO Position Statement Issued 2011, Updated 2013